{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:02:18Z","timestamp":1794283338889,"version":"4.9.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>CANDOR (NCT03158688) is a phase 3, randomized, open-label trial comparing carfilzomib, daratumumab, and dexamethasone (KdD) vs carfilzomib and dexamethasone (Kd) in adults with relapsed\/refectory multiple myeloma (RRMM) with 1 to 3 prior therapies. The CANDOR study met its primary end point of progression-free survival (PFS) in the primary analysis. Here, we report the final analysis of the study, including secondary end points and subgroup analyses thereof. The median follow-up was 50\u00a0months. Patients treated with KdD had higher minimal residual disease\u2013negative (MRD\u2212) achievement rates (28% vs 9%; odds ratio [OR], 4.22; 95% confidence interval [95%\u00a0CI], 2.28-7.83) and MRD\u2013 complete response rates (22% vs 8%; OR, 3.55; 95% CI, 1.83-6.88) than those treated with Kd. Median PFS was 28.4\u00a0months for KdD vs 15.2\u00a0months for Kd (hazard ratio [HR], 0.64; 95%\u00a0CI, 0.49-0.83). Median overall survival (OS) for KdD was 50.8\u00a0months vs 43.6\u00a0months for Kd (HR, 0.78 [0.60-1.03]; P\u00a0= .042). Trends toward improved OS occurred in predefined subgroups, including patients refractory to lenalidomide (KdD, not reached vs Kd, 38.2\u00a0months; HR, 0.69 [0.43-1.11]) and refractory to proteasome inhibitor (KdD, 43.2\u00a0months vs Kd, 30.0\u00a0months; HR, 0.70 [0.45-1.09]), and there was significant improvement in patients with high-risk cytogenetics (KdD, 34.3\u00a0months vs Kd: 17.1\u00a0months; HR, 0.52 [0.29-0.94]). No new safety signals were identified. In summary, the final analysis of CANDOR confirmed the PFS benefit and showed a trend in OS benefit with KdD vs Kd. These findings reinforce KdD as a standard of care for RRMM, especially in clinically relevant patient subgroups. This trial was registered at www.clinicaltrials.gov as #NCT03158688.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010026","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T18:01:17Z","timestamp":1683741677000},"page":"3739-3748","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":104,"title":["Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study"],"prefix":"10.1182","volume":"7","author":[{"given":"Saad Z.","family":"Usmani","sequence":"first","affiliation":[{"name":"1Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-3352","authenticated-orcid":false,"given":"Hang","family":"Quach","sequence":"additional","affiliation":[{"name":"2University of Melbourne, St Vincent\u2019s Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"3University Hospital Salamanca\/ISAI, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"4Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"5Centre Hospitalier Universitaire de Poitiers, La Miletrie\/INSERM CIC 1402, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3604-2574","authenticated-orcid":false,"given":"David","family":"Siegel","sequence":"additional","affiliation":[{"name":"6John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"7University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Shu","sequence":"additional","affiliation":[{"name":"8Paraxel, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Li","sequence":"additional","affiliation":[{"name":"9Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"10National and Kapodistrian University of Athens, School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"issue":"10272","key":"2023072117502119200_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"2023072117502119200_bib2","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-022-01597-y","article-title":"Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence","volume":"36","author":"Misund","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"2023072117502119200_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/157339471002141124121404","article-title":"Biological and clinical implications of clonal heterogeneity and clonal evolution in multiple myeloma","volume":"10","author":"Bianchi","year":"2014","journal-title":"Curr Cancer Ther Rev"},{"key":"2023072117502119200_bib4","unstructured":"National comprehensive cancer network NCCN clinical practice guidelines in oncology (NCCN guidelines)\u2014multiple myeloma (version 5.2022). Accessed 5 August 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf."},{"issue":"4","key":"2023072117502119200_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-019-0200-1","article-title":"Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide","volume":"9","author":"Moreau","year":"2019","journal-title":"Blood Cancer J"},{"issue":"9","key":"2023072117502119200_bib6","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2023072117502119200_bib7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"2023072117502119200_bib8","volume-title":"Kyprolis (carfilzomib). Full prescribing information","year":"2022"},{"key":"2023072117502119200_bib9","volume-title":"Kyprolis (carfilzomib). Summary of product characteristics","year":"2022"},{"issue":"10245","key":"2023072117502119200_bib10","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2023072117502119200_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"2023072117502119200_bib12","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2023072117502119200_bib13","unstructured":"US Department of Health and Human Services. National Cancer Institute\n          . Common terminology criteria for adverse events (CTCAE)\u2014version 4.03. Available at:. Accessed 20 January 2023. https:\/\/www.eortc.be\/services\/doc\/ctc\/ctcae_4.03_2010-06-14_quickreference_5x7.pdf."},{"key":"2023072117502119200_bib14","first-page":"24","volume-title":"Proceedings of the Biopharmaceutical Section, American Statistical Association","author":"Robins","year":"1993"},{"issue":"6","key":"2023072117502119200_bib15","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.annonc.2022.04.013","article-title":"VP5-2022: updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)","volume":"33","author":"Moreau","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"2023072117502119200_bib16","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S1470-2045(22)00077-8","article-title":"Post-protocol therapy and informative censoring in the CANDOR study \u2013 authors' reply","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"2023072117502119200_bib17","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2023072117502119200_bib18","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"2023072117502119200_bib19","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"2023072117502119200_bib20","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023072117502119200_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11899-019-0495-9","article-title":"Should overall survival remain an endpoint for multiple myeloma trials?","volume":"14","author":"Holstein","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"10","key":"2023072117502119200_bib22","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: the (r)evolution of current therapy and a glance into future","volume":"105","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"2023072117502119200_bib23","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-22-0219","article-title":"Predicting the future: machine-based learning for MRD prognostication","volume":"28","author":"Pawlyn","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2023072117502119200_bib24","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A\u00a0large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"2023072117502119200_bib25","unstructured":"US Food and Drug Administration\n          . Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment\u2014guidance for industry. Accessed 29 August 2022. https:\/\/www.fda.gov\/media\/134605\/download."},{"issue":"10","key":"2023072117502119200_bib26","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1200\/JCO.20.01814","article-title":"Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR","volume":"39","author":"Avet-Loiseau","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2023072117502119200_bib27","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1182\/bloodadvances.2021006713","article-title":"Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma","volume":"6","author":"Martin","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2023072117502119200_bib28","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"2023072117502119200_bib29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"2023072117502119200_bib30","first-page":"19044","volume-title":"DARZALEX (daratumumab). Full prescribing information","year":"2021"},{"key":"2023072117502119200_bib31","volume-title":"SARCLISA (Isatuximab-irfc). Full prescribing information","year":"2020"},{"issue":"10292","key":"2023072117502119200_bib32","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3739\/2065478\/blooda_adv-2023-010026-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3739\/2065478\/blooda_adv-2023-010026-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T18:35:23Z","timestamp":1689964523000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/14\/3739\/495704\/Final-analysis-of-carfilzomib-dexamethasone-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":32,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,7,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010026","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]}}}